Mechanism of enhanced cardiac function in mice with hypertrophy induced by overexpressed Akt

J Biol Chem. 2003 Nov 28;278(48):47622-8. doi: 10.1074/jbc.M305909200. Epub 2003 Sep 16.

Abstract

Transgenic mice with cardiac-specific overexpression of active Akt (TG) not only exhibit hypertrophy but also show enhanced left ventricular (LV) function. In 3-4-month-old TG, heart/body weight was increased by 60% and LV ejection fraction was elevated (84 +/- 2%, p < 0.01) compared with nontransgenic littermates (wild type (WT)) (73 +/- 1%). An increase in isolated ventricular myocyte contractile function (% contraction) in TG compared with WT (6.1 +/- 0.2 versus 3.5 +/- 0.2%, p < 0.01) was associated with increased Fura-2 Ca2+ transients (396 +/- 50 versus 250 +/- 24 nmol/liter, p < 0.05). The rate of relaxation (+dL/dt) was also enhanced in TG (214 +/- 15 versus 98 +/- 18 microm/s, p < 0.01). L-type Ca2+ current (ICa) density was increased in TG compared with WT (-9.0 +/- 0.3 versus 7.2 +/- 0.3 pA/pF, p < 0.01). Sarcoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) protein levels were increased (p < 0.05) by 6.6-fold in TG, which could be recapitulated in vitro by adenovirus-mediated overexpression of Akt in cultured adult ventricular myocytes. Conversely, inhibiting SERCA with either ryanodine or thapsigargin affected myocyte contraction and relaxation and Ca2+ channel kinetics more in TG than in WT. Thus, myocytes from mice with overexpressed Akt demonstrated enhanced contractility and relaxation, Fura-2 Ca2+ transients, and Ca2+ channel currents. Furthermore, increased protein expression of SERCA2a plays an important role in mediating enhanced LV function by Akt. Up-regulation of SERCA2a expression and enhanced LV myocyte contraction and relaxation in Akt-induced hypertrophy is opposite to the down-regulation of SERCA2a and reduced contractile function observed in many other forms of LV hypertrophy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adenoviridae / genetics
  • Alkaline Phosphatase / chemistry
  • Animals
  • Blotting, Western
  • Body Weight
  • Calcium / metabolism
  • Calcium-Transporting ATPases / chemistry
  • Calsequestrin / chemistry
  • Dose-Response Relationship, Drug
  • Down-Regulation
  • Echocardiography
  • Electrophysiology
  • Enzyme Inhibitors / pharmacology
  • Fura-2 / pharmacology
  • Heart Ventricles / pathology*
  • Hypertrophy
  • Inhibitory Concentration 50
  • Kinetics
  • Lysophospholipase / chemistry
  • Mice
  • Mice, Transgenic
  • Muscle Cells / metabolism
  • Organ Size
  • Protein Serine-Threonine Kinases*
  • Proto-Oncogene Proteins / chemistry*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-akt
  • Rats
  • Reverse Transcriptase Polymerase Chain Reaction
  • Ryanodine / pharmacology
  • Ryanodine Receptor Calcium Release Channel / chemistry
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Thapsigargin / chemistry
  • Thapsigargin / pharmacology
  • Time Factors
  • Transfection
  • Transgenes
  • Up-Regulation

Substances

  • Calsequestrin
  • Enzyme Inhibitors
  • Proto-Oncogene Proteins
  • Ryanodine Receptor Calcium Release Channel
  • Ryanodine
  • Thapsigargin
  • Akt1 protein, rat
  • Protein Serine-Threonine Kinases
  • Proto-Oncogene Proteins c-akt
  • Lysophospholipase
  • Alkaline Phosphatase
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
  • Calcium-Transporting ATPases
  • Calcium
  • Fura-2